Profil
Sophie Binay is currently the Deputy CEO & Chief Scientific Officer at Acticor Biotech SAS.
Previously, she worked as the Director of Nonclinical Research & Development at Minka Therapeutics SA, the VP of Research & Early Clinical Development at PEP-Therapy SAS, and the Head of Translational Programs at Gustave Roussy Institute.
Postes actifs de Sophie Binay
| Sociétés | Poste | Début |
|---|---|---|
| ACTICOR BIOTECH SAS | Chief Tech/Sci/R&D Officer | 15/06/2021 |
Anciens postes connus de Sophie Binay
| Sociétés | Poste | Fin |
|---|---|---|
Minka Therapeutics SA
 Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Chief Tech/Sci/R&D Officer | - |
| Gustave Roussy Institute | Corporate Officer/Principal | - |
PEP-Therapy SAS
 PEP-Therapy SAS BiotechnologyHealth Technology PEP-Therapy SAS provides biotechnology development and research services. It engages in developing targeted therapies for the treatment of severe diseases, with an initial focus on cancer. The company was founded by Didier Decaudin, Fariba Némati, Angelita Rebollo and Antoine Prestat in January 2014 and is headquartered in Evry, France. | Chief Tech/Sci/R&D Officer | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACTICOR BIOTECH SAS | Health Technology |
| Entreprise privées | 3 |
|---|---|
Minka Therapeutics SA
Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Health Technology |
PEP-Therapy SAS
PEP-Therapy SAS BiotechnologyHealth Technology PEP-Therapy SAS provides biotechnology development and research services. It engages in developing targeted therapies for the treatment of severe diseases, with an initial focus on cancer. The company was founded by Didier Decaudin, Fariba Némati, Angelita Rebollo and Antoine Prestat in January 2014 and is headquartered in Evry, France. | Health Technology |
| Gustave Roussy Institute |
